A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H Clinical Trial

Official title:
A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Status Recruiting

Clinical Trial Summary

Evaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05890742
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact	Jiayu Wen
Phone	+86-18114928232
Email	jiayu.wen@innovnentbio.com
Status	Recruiting
Phase	Phase 3
Start date	May 25, 2023
Completion date	July 15, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06004713` - Registry Study in MSI/dMMR Solid Tumors
Completed	`NCT02482168` - Study of the CD40 Agonistic Monoclonal Antibody APX005M	Phase 1
Not yet recruiting	`NCT06346197` - Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas	Phase 3
Recruiting	`NCT04969029` - Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations	Phase 2
Completed	`NCT03775850` - A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors	Phase 1
Not yet recruiting	`NCT05468138` - PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery	Phase 2
Recruiting	`NCT04636008` - Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer	Phase 1/Phase 2